Streetbeat News

Stock Prices

GILD

Gilead Sciences (NYSE:GILD) has seen a decrease in short interest, with the short percent of float dropping 4.37% since the last report. The company has 19.50 million shares sold short, representing 1.75% of available shares, with a cover time of 3.36 days. This decline in short interest may indicate a more bullish sentiment among investors, although it doesn't necessarily predict a near-term price rise. Gilead has a lower short interest compared to its peer group average of 4.35%.

Portfolio Pulse from Benzinga Insights

November 22, 2023 | 6:45 pm

SO

Southern (NYSE:SO) has seen a 3.7% decrease in short interest since its last report, with 11.30 million shares sold short, representing 1.04% of available shares. The average time to cover these short positions is 2.73 days. A decrease in short interest can indicate a more bullish sentiment towards the stock. Southern has less short interest compared to its peer group average of 2.25%.

Portfolio Pulse from Benzinga Insights

November 22, 2023 | 6:45 pm

CEG

Constellation Energy (NYSE:CEG) has seen a 15.7% decrease in short interest since its last report, with 5.73 million shares sold short, representing 2.04% of its float. The average time to cover these short positions is 4.06 days. A decrease in short interest can indicate a more bullish sentiment towards the stock. Constellation Energy has a lower short interest compared to its peer group average of 2.20%.

Portfolio Pulse from Benzinga Insights

November 22, 2023 | 6:45 pm

META

Meta Platforms Inc. (NASDAQ:META) hit a 52-week high, trading over $342, with a 174% increase this year and a 210.90% rise over the past year. Despite a high Fwd P/E of 23.5, analysts remain bullish, with Tigress Financial upgrading META to Strong Buy and a $435 price target, and Stifel maintaining a Buy rating with a $405 target. META's shift to Generative AI and strong Q3 earnings, with $34.15 billion in revenue and $4.39 EPS, contribute to its positive outlook.

Portfolio Pulse from Surbhi Jain

November 22, 2023 | 6:37 pm

RELI

Reliance Global (RELI) shares are up following the withdrawal of its proposed underwritten public offering and the announcement of a Letter of Intent to acquire a benefits enrollment company.

Portfolio Pulse from Benzinga Newsdesk

November 22, 2023 | 6:37 pm

ADSK

Mizuho analyst Matthew Broome downgraded Autodesk's price target from $220 to $200 while maintaining a Neutral rating, citing concerns over Autodesk's new transaction model that requires indirect customers to transact directly with the company. This change, which began in Australia and will roll out globally, could strain relationships with resellers. Despite solid Q3 results, Autodesk's FY25 revenue guidance of 9%+ growth is below expectations and its long-term target, reflecting a challenging operating environment. Autodesk's stock dropped 5.59% to $205.51.

Portfolio Pulse from Nabaparna Bhattacharya

November 22, 2023 | 6:34 pm

BBAR

Banco BBVA Argentina's stock is trading lower following the release of their Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

November 22, 2023 | 6:33 pm

CME

Over the past 20 years, CME Group (NASDAQ:CME) has delivered an average annual return of 14.75%, outperforming the market. A $100 investment in CME stock two decades ago would be worth $1,578.94 today. CME Group currently has a market cap of $77.64 billion. The article highlights the impact of compounded returns on investment growth over time.

Portfolio Pulse from Benzinga Insights

November 22, 2023 | 6:30 pm

DLTR

Over the past 20 years, Dollar Tree (NASDAQ:DLTR) has produced an average annual return of 12.52%, outperforming the market. A $100 investment in DLTR 20 years ago would now be worth $1,092.37. The company's current market capitalization stands at $25.41 billion.

Portfolio Pulse from Benzinga Insights

November 22, 2023 | 6:30 pm

SHOT

Safety Shot Inc (NASDAQ:SHOT) responded to a short report by Capybara Research, which led to a selloff in SHOT shares. The report questioned the legitimacy of Safety Shot's flagship product and the company's founders. Safety Shot called the report malicious and defamatory, highlighting past lawsuits against Capybara Research for fraudulent articles. CEO Brian John invited skeptics to try the product and urged investors to conduct due diligence. Safety Shot's beverage, aimed at reducing blood alcohol content, is launching in December. Despite the selloff, SHOT is up 460% YTD.

Portfolio Pulse from Adam Eckert

November 22, 2023 | 6:29 pm